Complete cytologic remission of V600E BRAF-mutant melanoma-associated leptomeningeal carcinomatosis upon treatment with dabrafenib

Journal of Clinical Oncology

Volumn 33, Issue 28, 2015, Pages e109-e111

  Wilgenhof, Sofie ^a   Neyns, Bart ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; FLUORODEOXYGLUCOSE F 18; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; CANCER REGRESSION; CANCER SURGERY; CARCINOMATOUS MENINGITIS; CASE REPORT; CELL THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DARIER DISEASE; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MELANOMA; MELANOMA METASTASIS; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; ANTAGONISTS AND INHIBITORS; COMPASSIONATE USE; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; MENINGEAL CARCINOMATOSIS; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHENOTYPE; REMISSION; SECONDARY; SKIN TUMOR; TIME FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COMPASSIONATE USE TRIALS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMIDAZOLES; MAGNETIC RESONANCE IMAGING; MELANOMA; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; MUTATION; OXIMES; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; REMISSION INDUCTION; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84944210339     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.7298     Document Type: Article

References (9)

1. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002
2. Curtin JA, Fridlyand J, Kageshita T, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135-2147, 2005
3. Yang H, Higgins B, Kolinsky K, et al: RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 70: 5518-5527, 2010
4. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819, 2010
5. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
6. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365, 2012
7. Long GV, Trefzer U, Davies MA, et al: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 13: 1087-1095, 2012
8. Harstad L, Hess KR, Groves MD: Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol 10: 1010-1018, 2008
9. Simeone E, De Maio E, Sandomenico F, et al: Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): A case report. J Med Case Rep 6: 131, 2012